Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma

In head and neck squamous cell carcinoma (HNSCC) tumors that over-expresses huEGFR, the anti-EGFR antibody, cetuximab, antagonizes tumor cell viability and sensitizes to radiation therapy. However, the immunologic interactions between cetuximab and radiation therapy are not well understood. We trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Won Jong, Erbe, Amy K., Schwarz, Ciara N., Jaquish, Abigail A., Anderson, Bryce R., Sriramaneni, Raghava N., Jagodinsky, Justin C., Bates, Amber M., Clark, Paul A., Le, Trang, Lan, Keng-Hsueh, Chen, Yi, Kim, KyungMann, Morris, Zachary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689006/
https://www.ncbi.nlm.nih.gov/pubmed/33281820
http://dx.doi.org/10.3389/fimmu.2020.591139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689006/
https://www.ncbi.nlm.nih.gov/pubmed/33281820
http://dx.doi.org/10.3389/fimmu.2020.591139

Ejemplares similares